FNDX.c's Product to fight Hospital-Acquired Infections Approximately 1 in 31 patients on any given day acquire an infection from being in the hospital, creating a significant cost burden on the Canadian medical system and undue suffering. Source: https://www.cdc.gov/hai/data/index.html
Disinfectants alone don't seem to be doing enough to keep patients healthy while in hospital. Seeing this gap in the market, FendX Technologies (Ticker: FNDX.c) has licensed award-winning nanotechnology from McMaster University, to develop products for commercialization that reduce the spread of pathogens in a unique way.
FNDX's nanotechnology repels viruses, bacteria, and blood. Since the pathogens are repelled rather than killed, it is not expected to contribute to antibiotic resistance or create superbugs as disinfectants do.
The company's flagship product is REPELWRAP™, a film that can be applied to surfaces to help keep them safe. Once REPELWRAP™ is applied, it will do its job of helping to keep a surface clean constantly, rather than only for a short while like disinfectants.
FNDX has a short commercialization timeline for REPELWRAP™, expecting to launch it in 2024. Learn more here: https://fendxtech.com Posted on behalf of FendX Technologies Inc.